Figure 2

Salirasib inhibits HCC cells proliferation. HepG2 (left column), Huh7 (central column), and Hep3B (right column) cells were seeded in 96-wells plates and incubated with DMSO (control) or the indicated doses of salirasib (n = 8 at each dose and time-point). Identical experiments were performed in FBS-cultured cells (A-C), in EGF- (D-F) and IGF2-stimulated (G-I) cells. BrdU incorporation was assessed after 1 (FBS, EGF, IGF2) or 2 days (FBS only) treatment with salirasib. In the growth factor stimulation experiments, a FBS group - consisting of FBS-cultured untreated cells - was included as a positive control. Data are presented as mean ± SEM. * P < 0.05, ** P < 0.01 and *** P < 0.001 in treated groups versus control group.